Mustang Bio (MBIO) Stock Analysis
NASDAQHealthcareBiotechnology
What Mustang Bio does
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Key metrics
ETFs linked to MBIO
Broad-market and Healthcare sector ETFs an investor holding Mustang Bio is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how MBIO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze MBIO in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Mustang Bio?
- Mustang Bio trades under the ticker MBIO on NASDAQ.
- Which exchange is MBIO listed on?
- MBIO is listed on NASDAQ.
- What sector does Mustang Bio operate in?
- Mustang Bio is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze MBIO in a portfolio?
- PortView shows MBIO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.